- EPA Moves to Cancel Key Climate Regulations That Limit Pollution
- Wisconsin Reports First West Nile Virus Case of the Year
- Deion Sanders Shares Bladder Cancer Journey, Urges Others to Get Checked
- Cardiac Rehab Is Safe for Folks With A-Fib, And Might Even Help Ease It
- Blood-Based Colon Cancer Tests Work, But Many Patients Skip Follow-Up
- ‘Ultra-Processed’ Foods Could Hike Your Odds for Lung Cancer
- Over 60? Healthy Lifestyle Change May Help Boost Your Brain
- ‘Tongue Swallowing Prevention’: The Wrong First Move When Cardiac Arrest Strikes
- FDA Urges Restrictions, Education on Illegal 7-OH Opioid Products
- Federal Judge Halts Plan to Defund Planned Parenthood Through Medicaid
New Test Helps Diagnose Intellectual Disability in Children

A new test to help diagnose developmental delays and intellectual disability in children based on genetic abnormalities has been approved by the U.S. Food and Drug Administration.
The Affymetrix CytoScan DX Assay scans the entire genetic code from a blood sample and detects chromosomal variations that can lead to developmental and learning problems in children, the agency said Friday in a news release.
Intellectual disability affects as many as 3 percent of children in the United States, the agency said.
Analysis of 960 blood specimens found the new test was better at detecting chromosomal abnormalities that could lead to intellectual disability than other standard tests, the FDA said.
The new test is produced by Affymetrix Inc., based in Santa Clara, Calif.
More information
Medline Plus has more about intellectual disability.
Source: HealthDay
Copyright © 2025 HealthDay. All rights reserved.